Showing 2771-2780 of 3069 results for "".
- Zydus Lifesciences Scores FDA Nod for Generic Acne Drughttps://practicaldermatology.com/news/zydus-lifesciences-scores-fda-nod-for-generic-acne-drug/2461791/The U.S. Food and Drug Administration (FDA) has given its nod to Zydus Lifesciences’ generic antibiotic minocycline hydrochloride extended-release tablets for the treatment of moderate to severe acne in 55 mg, 65 mg, and 115 mg doses, the Company reports. Minocycline hyd
- EAACI News: Barzolvolimab May Help Tame Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/eaaci-news-barzolvolimab-may-help-tame-chronic-spontaneous-urticaria/2461786/Celldex Therapeutics, Inc.’s barzolvolimab is looking good in chronic spontaneous urticaria, according to data from the Phase 1b single-dose cholinergic cohort included in the chronic inducible urticaria (CIndU) trial that was presented at the European Academy of Allergy and Clini
- DFD-29 Shows No Major impact on Healthy Microbial Flora in Rosaceahttps://practicaldermatology.com/news/dfd-29-shows-no-major-impact-on-healthy-microbial-flora-in-rosacea/2461785/DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) doesn’t disrupt the microbial floral in healthy adults with papulopustular rosacea, according to data from a Phase 1 clinical trial. DFD-29 is being developed for the treatment of papulopustular ros
- EULAR News: Tremyfa Data Shows Sustained Improvements in PsAhttps://practicaldermatology.com/news/eular-news-tremyfa-data-showing-sustained-improvements-in-psa/2461755/Tremfya (guselkumab) provides sustainable improvements in all minimal disease activity (MDA) domains through week 48 in adults with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR), according to new data
- American Skin Association, National Council for Skin Cancer Prevention Partner for Sun Safetyhttps://practicaldermatology.com/news/american-skin-association-national-council-for-skin-cancer-prevention-partner-for-sun-safety/2461745/The American Skin Association has partnered with the National Council on Skin Cancer Prevention and its broad coalition of member organizations to designate May 26. 2023 as "Don't Fry Day." "Don't Fry Day is the perfect way to jump start the summer holi
- It's Going to Be a Scorcher: Experts Predict Extreme UV Index Ratings This Memorial Dayhttps://practicaldermatology.com/news/its-going-to-be-a-scorcher-experts-predict-extreme-uv-index-ratings-this-memorial-day/2461739/A dozen U.S. cities are expected to have extreme ultraviolet (UV) index ratings (10+) this Memorial Day and throughout the summer, according to data from the
- DermTech Appoints Bret Christensen as New President and CEOhttps://practicaldermatology.com/news/dermtech-appoints-bret-christensen-as-new-president-and-ceo/2461707/DermTech announced the appointment of Bret Christensen as president, chief executive officer, and a member of the board of directors. Mr. Christensen, who was previously chief commercial officer of Insulet, succeeds Dr. John Dobak, who stepped down as president, CEO and a dir
- Cynosure Taps New CEOhttps://practicaldermatology.com/news/cynosure-taps-new-ceo/2461676/Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023. He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition. "Nadav has an incredibly strong track record of operation
- 2023 Medscape Report: Physician Salaries Rise as Gender Gap Narrowshttps://practicaldermatology.com/news/2023-medscape-report-physician-salaries-rise-as-gender-gap-narrows/2461663/Doctor salaries continue to rise as the gender gap narrows, according to the 2023 Medscape Physician Compensation Report. The largest difference for women was seen in primary care, but the disparity also narrowed within specialties, from a 36% difference i
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, plac